Halozyme Therapeutics Inc (HALO)

Working capital turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Total current assets	US$ in thousands	746,424	879,006	765,745	615,019	739,013	653,201	541,938	988,689	926,287	1,017,300	999,750	941,719	554,764	498,895	500,358	467,971	543,436	342,041	391,706	409,036
Total current liabilities	US$ in thousands	112,494	115,185	116,393	91,919	130,789	109,384	199,512	111,691	117,147	113,153	114,251	107,421	421,385	26,976	26,073	42,002	85,637	108,041	135,417	138,662
Working capital turnover		1.28	1.00	1.16	1.31	1.06	1.04	1.40	0.53	0.54	0.51	0.46	0.39	2.01	0.42	0.38	0.39	0.43	0.87	0.71	0.66

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $810,397K ÷ ($746,424K – $112,494K)
= 1.28

The working capital turnover for Halozyme Therapeutics Inc. fluctuated over the past eight quarters. In the most recent quarter, Q4 2023, the working capital turnover stood at 1.31, indicating that the company generated $1.31 in revenue for every dollar of working capital invested during that period.

The trend in the working capital turnover ratio shows some variability, with Q2 2022 having the highest ratio of 1.42 and Q1 2022 recording the lowest ratio of 0.54. This suggests that in Q2 2022, the company was able to generate significant revenue relative to its working capital, while in Q1 2022, the company's efficiency in utilizing its working capital to generate revenue was relatively low.

Overall, the working capital turnover ratio for Halozyme Therapeutics Inc. has shown fluctuations over the analyzed period, indicating differences in the company's operational efficiency and ability to generate revenue from its working capital. Further analysis and comparison with industry benchmarks may provide additional insights into the company's performance.